The results of the PRODIGE-24 trial are among the most significant of the last quarter century in terms of their impact on the treatment of patients with pancreatic adenocarcinoma. The administration of mFOLFIRINOX resulted in almost a doubling of 3 yr DFS (the primary endpoint) and also extended t...